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1University of Florida, Gainesville, FL, USA; 2University of
South Florida,Tampa, FL, USA; 3Florida Department of Health,
St. Petersburg, FL, USA
OBJECTIVE: This study presents an analysis of a
smoking cessation program implemented by the Healthy
Start Coalition of Pinellas County. The purpose of this
program is to discourage maternal smoking during preg-
nancy, with the anticipation of promoting a positive birth
experience.
METHODS: A total of 1144 pregnant women were
referred to the program from December 1997 to Decem-
ber 1999. Of those, 626 did not receive smoking cessa-
tion services, 177 began but did not continue with the
services and 341 remained in the program until giving
birth. The women were given the smoking cessation
manual “A Pregnant Woman’s Self-Help Guide to Quit
Smoking” and were provided with individualized coun-
seling sessions. Participants were followed until giving
birth. Outcome measures included birthweight, SGA
births, prematurity, and the number of cigarettes reported
at entry and exit.
RESULTS: One-way analysis of variance was used to
perform comparisons between each group of subjects, i.e.
those that did not receive services, those that entered but
did not complete the program, and those that completed
the program. The analysis revealed a statistically signiﬁ-
cant difference in mother’s age (p = .021). Signiﬁcance
was further noted in the change in the number of 
cigarettes smoked (p < .001), the number of cigarettes
reported at entry into the program (p < .001), and the
number of cigarettes reported at exit (p < .001). This
analysis failed to reveal a signiﬁcant difference for 
prematurity (p = .228) and the birthweight of the baby
(p = .05). There was, however, a signiﬁcant difference
with SGA (p = .016).
CONCLUSION: With the exception of SGA, the results
of the birth outcome measures presented in this data
failed to support the ﬁndings of other researchers, who
suggest that smoking cessation reduces the rate of low
birth weight and premature births. Whereas this data did
not provide support for improved birth outcomes, bene-
ﬁts of the intervention was demonstrated with the sig-
niﬁcance reported in the reduction in the number of 
cigarettes smoked.
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OBJECTIVE: To determine whether preferred drug status
in a three-tier copayment structure adversely affects
patient adherence, days of therapy, and switching for 
triptans and anti-depressants (SSRI’s).
METHODS: We conducted a longitudinal, retrospective
claims database study using two years of claims data 
from a national pharmaceutical beneﬁts management
company. Claims for two chronic conditions, depression
and migraine were examined for patients on three-tier
copayment plans from 18 health plans. In the SSRI class
two status changes were examined: one drug was changed
from a non-preferred to neutral status (n = 2,391) and
the second drug was changed from preferred to non-
preferred (n = 199); in the triptan class the drug studied
was changed from a preferred to non-preferred status.
Average rates of patient adherence, drug exposure, days
of therapy, and switching from one drug to another were
calculated.
RESULTS: In the SSRI class 47% of patients continued
using the non-preferred drug after it was placed in a
neutral status, 35% discontinued therapy, 2% switched
to a preferred product, and 16% terminated beneﬁts 
coverage (i.e., changed insurance plans) before the drug
status changed. In the triptan class 29% of patients 
continued using the drug, 54% discontinued therapy, 4%
switched to another product, and 13% terminated bene-
ﬁts coverage. Drug utilization decreased during the post-
change period among patients continuing on the same
product. Differences in drug utilization between patients
continuing on the same drug and those switching to a dif-
ferent preferred drug were non-existent in the triptan
class and minimal in the SSRI class (i.e., only days of
therapy pre- and post-change were signiﬁcantly different).
CONCLUSIONS: Changing a drug from a preferred to
non-preferred status has little effect on patients’ switch-
ing behavior, but it does affect whether they choose 
to remain in the health plan or whether they choose to
continue treatment and adherent they are with the treat-
ment regimen, which may result in decreases in patient
satisfaction and long-term increases in medical resource
utilization.
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